This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
19 - 21 October, 2026
The Westin Miyako Kyoto
BOOK NOW
Menu
BOOK NOW
keyboard_arrow_right

Main Conference Day 1 - JT (Japan Time, GMT+09:00)

keyboard_arrow_leftSearch & Filter
search
Main Conference Day 1 - JT (Japan Time, GMT+09:00)
search
Showing 1 of 1 Streams
08:30 - 09:00
Morning Registration
Showing 1 of 1 Streams
09:00 - 09:30
Beyond Conventional Antibodies: Innovative Strategies in Antibody Engineering and Drug Discovery
  • Switch-Ig technology designed to exploit the unique features of the tumour microenvironment
  • An antibody engineering platform integrating AI and laboratory automation
  • A first-in-class multispecific antibody for celiac disease targeting the gluten peptide/HLA complex
  • Taichi Kuramochi - Head of Biologics Discovery, Chugai Pharmaceutical
Showing 1 of 1 Streams
09:30 - 10:00
Accelerated Antibody Discovery: Platforms for High-Speed Generation of Fully Human Therapeutics
10:00 - 10:30
High-throughput discovery and engineering of pHLA-targeting therapeutics
  • Garrett Rappazzo - Senior Scientist, Adimab LLC
Morning Break
Showing 1 of 1 Streams
10:30 - 11:15
Morning Break & Networking
Showing 1 of 1 Streams
11:15 - 11:45
Precision Immunomics: Leveraging Large-Scale Repertoire Analysis for Lead Identification and Diagnostic Insight
11:45 - 12:15
High-Throughput Mapping: Moving from Discovery to Deep Lead Characterization
Showing 1 of 1 Streams
12:15 - 12:45
EMLy™: Powering Smarter, Faster, and Scalable AI-Guided Biologics Development
  • Alfred Lim, PhD - Director of Lab Research, Etcembly Ltd.
Lunch
Showing 1 of 1 Streams
12:45 - 13:45
Lunch Break & Networking
Showing 1 of 1 Streams
13:45 - 14:15
Marriage of single-cell and cell-free technologies for rapid and comprehensive generation of high-performance antibodies
  • Shoji Ohuchi, Ph.D., MBA - Co-CEO, CSO and CTO, iBody Inc.
14:15 - 14:45
Emerging Modalities in Extracellular Targeting: The Future of Degraders, PROTACs, and Context-Dependent Binding
14:45 - 15:15
Advancing Next-Generation Antibody Drug Discovery through Chiome’s DoppeLib Platform and Integrated Drug Discovery Partnerships
  • Kiyotoshi Mori - Head of Research Division, Chiome Bioscience Inc.
Afternoon Break
Showing 1 of 1 Streams
15:15 - 16:00
Afternoon Break & Networking
Showing 1 of 1 Streams
16:00 - 16:30
Next-Generation Engineering Challenges: From Multispecifics to Conditionally Active Biologics
Showing 1 of 1 Streams
16:30 - 17:30
Innovation Spotlight: Highlighting Breakthrough Clinical Data & Developments
  • A clinical showcase of global Innovation:
  • Multispecifics
  • Next-gen ADCs.
  • Pipeline Technical Breakthroughs
  • Clinical Progress
END OF DAY 1
Showing 1 of 1 Streams
17:30 - 17:35
END OF MAIN CONFERENCE DAY 1
Pre-Conference Workshop Day
NextMain Conference Day 2
Filter
Streams
Choose Day